Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio

When Joe Jimenez left Novartis, one thing was clear: After 11 years in the biopharma biz and eight at the Swiss drugmaker’s helm, he was ready to build something from scratch. Now, he’s unveiling that something: Aditum Bio, a biotech investment firm he co-founded with Mark Fishman, M.D., former president of the Novartis Institutes for BioMedical Research.